Harvard University has spun out NuProbe to commercialise a molecular blood test based on research by Peng Yin and David Zhang at the Wyss Institute.
NuProbe, a US-based medical diagnostics technology developer, has been spun out from Harvard University’s Wyss Institute for Biologically Inspired Engineering with $11m in series A funding.
The series A round was co-led by Sequoia Capital China, an affiliate of VC firm Sequoia Capital, and hedge fund manager Serica Partners. It also featured WuXi AppTec Corporate Ventures, healthcare group WuXi AppTec’s corporate venturing unit.
NuProbe has developed a molecular blood test that helps medical researchers promptly detect rare genetic variants that…
